Pfizer Inc. $PFE Shares Sold by Aull & Monroe Investment Management Corp

Aull & Monroe Investment Management Corp reduced its stake in Pfizer Inc. (NYSE:PFE) by 13.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 40,265 shares of the biopharmaceutical company’s stock after selling 6,100 shares during the quarter. Aull & Monroe Investment Management Corp’s holdings in Pfizer were worth $976,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in PFE. Pacer Advisors Inc. lifted its holdings in shares of Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after acquiring an additional 17,957,928 shares during the last quarter. Amundi increased its stake in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the period. Nuveen LLC purchased a new stake in Pfizer during the 1st quarter worth approximately $389,861,000. Goldman Sachs Group Inc. increased its stake in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock worth $670,407,000 after buying an additional 9,041,990 shares during the period. Finally, Vanguard Group Inc. increased its stake in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after buying an additional 4,629,976 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.2%

NYSE PFE opened at $24.52 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm’s fifty day moving average price is $24.89 and its 200 day moving average price is $24.11. The company has a market capitalization of $139.38 billion, a price-to-earnings ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $29.36.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on PFE. Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.